1 tion-dependently self-administered vaporized sufentanil.

2 onse (nosepoke) to receive 10 s of vaporized sufentanil, a potent opioid, in 2 h daily sessions.

3 otentials (LFP) in primary visual cortex, in sufentanil-anaesthetized marmoset monkeys.

4 escalation baseline levels of responding for sufentanil and mechanical sensitivity.

5 during sedation with continuous infusions of sufentanil and midazolam.

6                                        Serum sufentanil concentrations significantly correlated with

7         Exposure to the potent full agonists sufentanil, dihydroetorphine, etorphine, etonitazine, an

8 not short access (ShA; 1 h/day) to vaporized sufentanil escalated their drug intake over time and exh

9 istate 13-acetate (PMA), not only attenuates sufentanil inhibition of evoked cAMP formation but rever

10 pioid inhibition to enhancement and restores sufentanil inhibitory responsiveness.

11 at the mu-selective opiate receptor agonist, sufentanil, produces a naloxone-reversible, concentratio

12  significantly correlated with the number of sufentanil vapor deliveries.

13  These findings demonstrate that the operant sufentanil vapor self-administration model has both face

14  (ie, after the return to extended access to sufentanil vapor), LgA rats again developed naloxone-pre

15 d receptors in the reinforcing properties of sufentanil vapor.

16 ted a significant increase in responding for sufentanil when given the preferential mu-opioid recepto